Prostate cancer: potential targets of anti-proliferative and apoptotic signaling pathways

Prostate cancers are genetically and phenotypically heterogenous. The heterogeneous nature of prostate cancer may be a consequence of mutations in different cell types (basal stem, transit amplifying or luminal cells) resulting in different malignant maturation pathways. One consistent characterizat...

Full description

Saved in:
Bibliographic Details
Published in:The international journal of biochemistry & cell biology 2005-04, Vol.37 (4), p.707-714
Main Authors: Uzgare, Aarti R., Isaacs, John T.
Format: Article
Language:English
Subjects:
Apoptosis
Cancer stem cell
Cell Division
Humans
Male
Novel therapies
Prostate carcinogenesis
Prostatic Neoplasms - metabolism
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
Signal Transduction
Survival pathways
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prostate cancers are genetically and phenotypically heterogenous. The heterogeneous nature of prostate cancer may be a consequence of mutations in different cell types (basal stem, transit amplifying or luminal cells) resulting in different malignant maturation pathways. One consistent characterization of these cancers, however, is their eventual progression to a hormonal refractory state. The development of effective novel therapeutic strategies requires an understanding of the mechanisms for the development of such a refractory state. Targeting proliferative and survival pathways provides a rationale for drug design and development for hormone refractory prostate cancer. Prostate cancer cells, however, develop an enhanced redundancy in downstream survival signaling. Hence, new combinational therapies must be developed with the understanding that compensatory mechanisms evolve under selective pressure.
ISSN:1357-2725
1878-5875
DOI:10.1016/j.biocel.2004.11.018